SOURCE: Biovitrum

June 21, 2010 10:14 ET

Change of company name for Biovitrum AB (publ)

STOCKHOLM, SWEDEN--(Marketwire - June 21, 2010) - Biovitrum AB (publ) will be listed under its new company name, Swedish Orphan Biovitrum AB (publ) with effect from June 24, 2010.

+-----------------------+------------+
|New short name:        |SOBI        |
+-----------------------+------------+
|Unchanged ISIN code:   |SE0000872095|
+-----------------------+------------+
|Unchanged Round lot:   |1           |
+-----------------------+------------+
|Unchanged orderbook ID:|36316       |
+-----------------------+------------+

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum is a Swedish based niche specialty pharmaceutical company with an international market presence. The company is focused on providing and developing specialist pharmaceuticals for rare disease patients with high medical needs. The portfolio consists of about 60 marketed products and an emerging late stage clinical development pipe-line. Our focus areas are: hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. Swedish Orphan Biovitrum had pro-forma revenues 2009e of about 2 BSEK and approximately 500 employees. The head office is located in Sweden and the share (STO:BVT ) is listed on NASDAQ OMX Stockholm. For more information please visitwww.sobi.com.

Swedish Orphan Biovitrum may be required to disclose the information provided herein pursuant to the Swedish Securities Markets Act. The information was provided for public release on June 21, 2010 at 4 p.m. CET.


[HUG#1425813]

Press release June 21 in pdf format: http://hugin.info/134557/R/1425813/373884.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction for further distribution is prohibited.

Contact Information

  • For more information please contact: Swedish Orphan Biovitrum AB (publ)

    Erik Kinnman, EVP Investor Relations
    Phone: +46 73 422 15 40
    Email Contact